Structural Basis for the Inhibition of Cyclin G‐Associated Kinase by Gefitinib

Gefitinib is the molecular target drug for advanced non‐small‐cell lung cancer. The primary target of gefitinib is the positive mutation of epidermal growth factor receptor, but it also inhibits cyclin G‐associated kinase (GAK). To reveal the molecular bases of GAK and gefitinib binding, structure a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohbayashi, Naomi, Murayama, Kazutaka, Kato‐Murayama, Miyuki, Kukimoto‐Niino, Mutsuko, Uejima, Tamami, Matsuda, Takayoshi, Ohsawa, Noboru, Yokoyoma, Shigeyuki, Nojima, Hiroshi, Shirouzu, Mikako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Full Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129943/
https://www.ncbi.nlm.nih.gov/pubmed/30214852
http://dx.doi.org/10.1002/open.201800177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129943/
https://www.ncbi.nlm.nih.gov/pubmed/30214852
http://dx.doi.org/10.1002/open.201800177

Ejemplares similares